M Ventures, Novartis Venture Fund and Pfizer Ventures are among the investors backing the DDR cancer therapeutics developer’s latest round, which took its total funding to $320m.
UK-based cancer therapy developer Artios Pharma secured $153m in a series C round on Tuesday from investors including pharmaceutical firms Merck Group, Novartis and Pfizer. Investment firms Omega Funds and TCG Crossover co-led the round, which included Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments, Soleus Capital, Piper Heartland Healthcare…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.